Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Innoviva, Inc.
  6. News
  7. Summary
    INVA   US45781M1018

INNOVIVA, INC.

(INVA)
  Report
Delayed Nasdaq  -  04:00 2022-10-04 pm EDT
12.23 USD   +3.64%
09/30Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update
AQ
09/14Innoviva, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/14Transcript : Innoviva, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-14-2022 11:10 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about INNOVIVA, INC.
09/30Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Ora..
AQ
09/14Transcript : Innoviva, Inc. Presents at Morgan Stanley 20th Annual Global Hea..
CI
09/08Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/23Innoviva : A. Risk Factors - Form 8-K
PU
08/22Innoviva : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
08/22Innoviva Completes Acquisition of La Jolla Pharmaceutical
BU
08/22Innoviva, Inc. completed the acquisition of La Jolla Pharmaceutical Company.
CI
07/27Innoviva : Q2 Earnings Snapshot
AQ
07/27Innoviva : Reports Second Quarter 2022 Financial Results and Highlights Recent Company Pro..
PU
07/27Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Pr..
BU
07/27Earnings Flash (INVA) INNOVIVA Posts Q2 Revenue $108.2M
MT
07/27Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
07/20Goldman Sachs Starts Innoviva at Neutral With $16 Price Target
MT
07/15Morgan Stanley Trims Innoviva's Price Target to $12 From $13, Underweight Rating Mainta..
MT
07/13Innoviva Selling Minority Stake in Asthma Therapies Company; Shares Rising in After-Hou..
MT
More most relevant news
All news about INNOVIVA, INC.
09/30Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Ora..
AQ
09/14Innoviva, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/14Transcript : Innoviva, Inc. Presents at Morgan Stanley 20th Annual Global Hea..
CI
09/08Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/23Innoviva : A. Risk Factors - Form 8-K
PU
08/23Innoviva, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/22Innoviva : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
08/22Innoviva, Inc. : Completion of Acquisition or Disposition of Assets, Other Events, Financi..
AQ
08/22Innoviva Completes Acquisition of La Jolla Pharmaceutical
BU
08/22Innoviva, Inc. completed the acquisition of La Jolla Pharmaceutical Company.
CI
More news
News in other languages on INNOVIVA, INC.
08/22Innoviva, Inc. (NasdaqGS:INVA) a finalisé l'acquisition de La J..
07/27Earnings Flash (INVA) INNOVIVA affiche un chiffre d'affaires de 108,2 millions de dolla..
07/27Innoviva, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le ..
07/20Royalty Pharma plc (NasdaqGS:RPRX) a finalisé l'acquisition..
07/13Innoviva vend une participation minoritaire dans une société spécialisée dans les théra..
07/11Mise à jour sectorielle : Les actions du secteur de la santé en ..
07/11Mise à jour sectorielle : Les actions du secteur de la santé ont..
07/11Mise à jour sectorielle : Soins de santé
07/11Innoviva accepte de privatiser La Jolla Pharmaceutical dans le cadre d'une transaction ..
07/11Innoviva, Inc. (NasdaqGS:INVA) a finalisé l'acquisition de la p..
More news
Analyst Recommendations on INNOVIVA, INC.
07/20Goldman Sachs Starts Innoviva at Neutral With $16 Price Target
MT
07/15Morgan Stanley Trims Innoviva's Price Target to $12 From $13, Underweight Rating Mainta..
MT
04/12Morgan Stanley Raises Innoviva's Price Target to $13 From $12, Maintains Underweight Ra..
MT
02/23Morgan Stanley Raises Innoviva's Price Target to $12 From $10, Maintains Underweight Ra..
MT
2020Innoviva : Morgan Stanley Adjusts Innoviva PT to $10 From $8, Maintains Underwe..
MT
More recommendations
Press releases
09/30Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Ora..
AQ
09/14Innoviva, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/08Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/23Innoviva : A. Risk Factors - Form 8-K
PU
08/23Innoviva, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More press releases
Upcoming event on INNOVIVA, INC.